Oncological and Surgical Outcomes of Pure Laparoscopic Radical Nephrectomy and Hand-Assisted Laparoscopic Radical Nephrectomy for pT1 Renal Cell Carcinoma: Comparison with Open Radical Nephrectomy.
10.4111/kju.2009.50.5.457
- Author:
Myong KIM
1
;
Yong Hyun PARK
;
Sang Eun LEE
;
Cheol KWAK
;
Hyeon Hoe KIM
Author Information
1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. hhkim@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Renal cell carcinoma;
Nephrectomy;
Laparoscopic surgery;
Treatment outcome
- MeSH:
Carcinoma, Renal Cell;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Kaplan-Meier Estimate;
Laparoscopy;
Length of Stay;
Nephrectomy;
Operative Time;
Retrospective Studies;
Treatment Outcome
- From:Korean Journal of Urology
2009;50(5):457-462
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We compared the surgical and oncologic outcomes of pure laparoscopic radical nephrectomy (PLRN) and hand-assisted laparoscopic radical nephrectomy (HLRN) with those of open radical nephrectomy (ORN) in patients with pT1 renal cell carcinoma (RCC). MATERIALS AND METHODS: Between 1999 and 2007, a total of 269 patients underwent PLRN (n=77), HLRN (n=87), and ORN (n=105) for pT1 RCC. Follow-up data consisted of clinical, pathologic, and oncologic results and were reviewed retrospectively. Kaplan-Meier survival curves were constructed for progression and survival endpoints. RESULTS: Mean operative time was 184.0, 164.0, and 132.6 minutes (p<0.001); mean estimated blood loss was 196.7, 147.8, and 232.6 ml (p<0.001); and mean postoperative hospital stay was 5.7, 7.2, and 7.8 days (p<0.001) for the PLRN, HLRN and ORN groups, respectively. The major complication rate after surgery was 2.6%, 2.3%, and 3.8%, respectively (p=0.807). Median follow-up periods were 32 months in the PLRN group, 48 months in the HLRN group, and 37 months in the ORN group. Five-year progression-free survival was 97.4%, 96.6%, and 98.1% (p=0.557), and 5-year cancer-specific survival was 98.7%, 96.6%, and 98.1% (p=0.508), respectively. CONCLUSIONS: PLRN and HLRN are safe treatment options with comparable oncologic results to ORN for pT1 RCC.
